Education
About Us
Working with TipRanks
Follow Us
Schrodinger, Inc. (SDGR)
:SDGR
SDGR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.60 - $28.47
Previous CloseN/A
Volume166.74K
Average Volume (3M)1.17M
Market Cap
$1.51B
Enterprise Value$1.36B
Total Cash (Recent Filing)$500.30M
Total Debt (Recent Filing)$116.16M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Jul 30, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding64,212,690
10 Day Avg. Volume1,424,749
30 Day Avg. Volume1,173,996
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)2.97
Price to Sales (P/S)0.00
P/FCF Ratio-10.42
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.63
Enterprise Value/Gross Profit9.40
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$31.88Price Target Upside55.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Schrodinger News
PremiumCompany Announcements
Schrodinger Announces Board Elections and Approvals
PremiumCompany Announcements
Schrödinger Appoints Richie Jain as New CFOBulls Say, Bears Say
Bulls Say
Biopharma Industry DisruptionSchrödinger's computational drug discovery platform will disrupt the biopharma industry, leading the transition to in silico drug discovery.
Safety ProfileSGR-1505 demonstrated a favorable safety profile compared to competing treatments, with some adverse events but no severe bilirubin increases.
Therapeutic PotentialPreliminary data demonstrated efficacy across a range of B-cell malignancies, supporting its therapeutic potential.
Bears Say
Bilirubin ConcernsConcerns arise about bilirubin levels potentially indicating a liver toxicity signal for the MALT1 class.
Differentiation ChallengesThere is skepticism about how SGR-1505 differentiates itself from competing assets, creating pressure on management to execute business development strategies.
Efficacy UncertaintyLess clear efficacy in DLBCL gives some pause, but the small trial size and range of selected doses mean Phase 2 will provide more clarity on a path forward.
Ownership Overview
2.33% Insiders
20.05% Mutual Funds
43.01% Other Institutional Investors
9.81% Public Companies and Individual Investors
SDGR FAQ
What was Schrodinger, Inc.’s price range in the past 12 months?
Schrodinger, Inc. lowest stock price was $16.60 and its highest was $28.47 in the past 12 months.
What is Schrodinger, Inc.’s market cap?
Schrodinger, Inc.’s market cap is $1.51B.
When is Schrodinger, Inc.’s upcoming earnings report date?
Schrodinger, Inc.’s upcoming earnings report date is Jul 30, 2025 which is in 33 days.
How were Schrodinger, Inc.’s earnings last quarter?
Schrodinger, Inc. released its earnings results on May 07, 2025. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.726 by -$0.094.
Is Schrodinger, Inc. overvalued?
According to Wall Street analysts Schrodinger, Inc.’s price is currently Undervalued.
Does Schrodinger, Inc. pay dividends?
Schrodinger, Inc. does not currently pay dividends.
What is Schrodinger, Inc.’s EPS estimate?
Schrodinger, Inc.’s EPS estimate is -0.83.
How many shares outstanding does Schrodinger, Inc. have?
Schrodinger, Inc. has 64,212,690 shares outstanding.
What happened to Schrodinger, Inc.’s price movement after its last earnings report?
Schrodinger, Inc. reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.726. Following the earnings report the stock price went up 0.675%.
Which hedge fund is a major shareholder of Schrodinger, Inc.?
Currently, no hedge funds are holding shares in SDGR
Schrodinger Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.88 (55.06% Upside)
$31.88 (55.06% Upside)
Blogger Sentiment
Bullish
SDGR Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 91.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.94%
12-Months-Change
Fundamentals
Return on Equity
-43.33%
Trailing 12-Months
Asset Growth
0.71%
Trailing 12-Months
Company Description
Schrodinger, Inc.
Schrodinger (SDGR) is a technology company that specializes in computational software solutions for the life sciences and materials science sectors. The company develops advanced molecular simulation software, enabling customers to accelerate their research and development processes, particularly in drug discovery and materials design. Schrodinger's platform helps scientists achieve more accurate predictions of molecular behavior, thereby reducing the need for physical experiments.
SDGR Company Deck
SDGR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth and strategic progress in partnerships and R&D, particularly in software and drug discovery. However, there were challenges, including a decline in professional services revenue, lower software gross margins, and increased net loss. Despite these issues, the company's overall outlook for 2025 remains positive.Read More>SDGR Stock 12 Month Forecast
Average Price Target
$31.88
▲(55.06%Upside)
Technical Analysis
Simulations Plus
―
Veeva Systems
―
Certara
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―